Valuation : Armata Pharmaceuticals, Inc.

Market Cap 200M 172M 161M 147M 277M 19.08B 278M 1.91B 747M 9.63B 750M 733M 31.94B P/E 2026 *
-2.88x
P/E 2027 * -3.72x
Enterprise Value 200M 172M 161M 147M 277M 19.08B 278M 1.91B 747M 9.63B 750M 733M 31.94B EV / Sales 2026 *
47x
EV / Sales 2027 * 36.3x
Free-Float
32.36%
Yield 2026 *
-
Yield 2027 * -
1 day-1.10%
1 week+5.29%
Current month+18.28%
1 month+12.34%
3 months-34.27%
6 months-52.98%
Current year-14.49%
1 week 4.73
Extreme 4.73
5.7
1 month 3.96
Extreme 3.96
5.7
Current year 3.48
Extreme 3.48
14.98
1 year 2.4
Extreme 2.4
16.34
3 years 0.9
Extreme 0.8981
16.34
5 years 0.83
Extreme 0.8311
16.34
10 years 0.83
Extreme 0.8311
16.34
Manager TitleAgeSince
Chief Executive Officer 70 10/07/2023
Director of Finance/CFO 42 15/08/2024
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 62 08/05/2019
Director/Board Member 66 11/02/2020
Director/Board Member 51 11/02/2020
Date Insider Type Main position Quantity % Market Cap. Importance
10/07/26 Tax

Chief Executive Officer

-14,041 0.0382%
24/04/26 Free

Director

51,280 0.1400%
14/03/26 Tax

Public Communications Manager

1,030 0.0028%
Change 5-day change 1-year change 3-year change Capi.($)
-1.10%+5.29%+114.80%+53.43% 200M
-1.59%-3.35%+52.37%+91.62% 69.54B
-2.84%+0.62%+43.55%+87.09% 64.97B
-3.57%+0.49%+35.74%+10.62% 26.51B
-0.14%-5.75%-12.90%+436.87% 25.89B
+0.30%-12.43%+2.08%-18.39% 25.64B
-0.96%+10.36%+283.06%+429.04% 20.22B
-2.64%+0.05%+28.80%-19.96% 19.98B
-3.36%-4.93%+2.30%+549.93% 15.69B
-1.09%+0.68%+45.51%+142.00% 13.49B
Average -1.77%-1.20%+59.53%+176.23% 28.21B
Weighted average by Cap. -1.93%-1.50%+50.01%+148.79%

Financials

2026 *2027 *
Net sales 4.25M 3.66M 3.43M 3.13M 5.9M 406M 5.92M 40.74M 15.89M 205M 15.96M 15.61M 680M 5.5M 4.74M 4.44M 4.06M 7.64M 526M 7.67M 52.72M 20.57M 265M 20.65M 20.2M 880M
Net income -76.6M -66.01M -61.89M -56.49M -106M -7.32B -107M -734M -286M -3.7B -288M -281M -12.25B -72M -62.04M -58.17M -53.1M -100M -6.88B -100M -690M -269M -3.47B -270M -264M -11.52B
Net Debt - -
Logo Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.
Employees
61
Date Price Change Volume
28/08/26 US$5.370 -1.10% 49,709
27/08/26 US$5.430 -0.37% 270,464
26/08/26 US$5.450 -1.98% 62,214
25/08/26 US$5.560 +7.54% 94,290
24/08/26 US$5.170 +1.37% 67,744
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.370USD
Average target price
17.50USD
Spread / Average Target
+225.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARMP Stock